- Trials with a EudraCT protocol (58)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (1)
58 result(s) found for: Thyroid neoplasm.
Displaying page 2 of 3.
| EudraCT Number: 2011-004701-24 | Sponsor Protocol Number: D4200C00097 | Start Date*: 2012-03-27 | |||||||||||
| Sponsor Name:AstraZeneca AB | |||||||||||||
| Full Title: An International, Randomised, Double-Blind, Two-Arm Study To Evaluate The Safety And Efficacy Of Vandetanib 150 And 300mg/Day In Patients With Unresectable Locally Advanced Or Metastatic Medullary ... | |||||||||||||
| Medical condition: Unresectable locally advanced or metastatic medullary thyroid cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: CZ (Completed) NL (Completed) IT (Completed) PL (Completed) GB (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2016-004390-41 | Sponsor Protocol Number: BLU-667-1101 | Start Date*: 2018-03-13 | ||||||||||||||||||||||||||
| Sponsor Name:Blueprint Medicines | ||||||||||||||||||||||||||||
| Full Title: A Phase 1/2 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors | ||||||||||||||||||||||||||||
| Medical condition: Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) NL (Completed) BE (Completed) | ||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||
| EudraCT Number: 2014-001225-33 | Sponsor Protocol Number: UC-0105/1401 | Start Date*: 2014-07-21 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:UNICANCER | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: Secured access to vemurafenib for patients with tumors harboring BRAF genomic alterations. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Patient with BRAF V600 mutation determined on the primary and/or metastatic lesion in the following pathologies: . NSCLC . Ovarian cancer . Cholangiocarcinoma . Thyroid cancer . Prostatic canc... | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: FR (Trial now transitioned) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2019-002319-25 | Sponsor Protocol Number: LOXO-RET-18037 | Start Date*: 2019-12-31 | |||||||||||||||||||||
| Sponsor Name:LOXO ONCOLOGY INCORPORATED | |||||||||||||||||||||||
| Full Title: A Multi-Center Expanded Access Program (EAP) for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors with Rearranged During Transfection (RET) Activation (LIBRETTO-201) | |||||||||||||||||||||||
| Medical condition: Advanced or metastatic solid tumors with activating Rearranged During Transfection (RET) alterations (and other evidence of RET activation) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: IT (Trial now transitioned) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
| EudraCT Number: 2022-000339-21 | Sponsor Protocol Number: JK08.1.01 | Start Date*: 2022-08-29 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:Salubris Biotherapeutics, Inc. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: A Phase 1/2, Multicenter, Open Label, Dose Escalation & Dose Expansion Study of JK08, an IL-15 Antibody Fusion Protein Targeting CTLA-4, Monotherapy or in Combination in Patients with Unresectable ... | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Unresectable Locally Advanced or Metastatic Cancer | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: BE (Trial now transitioned) ES (Ongoing) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2013-000885-13 | Sponsor Protocol Number: UC-0105/1303 | Start Date*: 2013-07-31 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:UNICANCER | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: Secured access to crizotinib for patients with tumors harboring a genomic alteration on one of the biological targets of the drug | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Patients with metastatic or unresectable locally advanced malignancies harboring specific genomic alterations regarding the biological crizotinib targets, and who are no more amenable to curative t... | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: FR (Completed) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2016-002243-42 | Sponsor Protocol Number: GCT1021-01 | Start Date*: 2016-10-25 | ||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:Genmab A/S | ||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of Axl-specific antibody-drug conjugate (enapotamab vedotin, HuMax®-AXL-ADC) in patients with solid tumors. | ||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Cancer of the ovary, cervix, endometrium, anaplastic thyroid, lung (non-small cell lung cancer [NSCLC]) or melanoma | ||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: DK (Completed) | ||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2020-004163-12 | Sponsor Protocol Number: 2020-012-GLOB1 | Start Date*: 2021-11-04 | |||||||||||||||||||||||||||||||
| Sponsor Name:Hutchison MediPharma Limited | |||||||||||||||||||||||||||||||||
| Full Title: An Open-Label Phase Ib/II Study of Surufatinib in Combination with Tislelizumab in Subjects With Advanced Solid Tumors | |||||||||||||||||||||||||||||||||
| Medical condition: Advanced Solid Tumors | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
| Trial protocol: ES (Ongoing) FR (Completed) | |||||||||||||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||||||||||||
| EudraCT Number: 2019-000212-28 | Sponsor Protocol Number: LOXO-RET-18036 | Start Date*: 2020-04-15 | ||||||||||||||||||||||||||
| Sponsor Name:Loxo Oncology, Inc. | ||||||||||||||||||||||||||||
| Full Title: A Phase 1/2 Study of the Oral RET Inhibitor LOXO-292 in Pediatric Patients with Advanced RET-Altered Solid or Primary Central Nervous System Tumors | ||||||||||||||||||||||||||||
| Medical condition: Pediatric Patients with Advanced RET-Altered Solid or Primary Central Nervous System Tumors | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
| Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||||||||||||
| Trial protocol: ES (Ongoing) FR (Trial now transitioned) DE (Trial now transitioned) DK (Trial now transitioned) IT (Trial now transitioned) | ||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||
| EudraCT Number: 2020-005016-21 | Sponsor Protocol Number: FW-2020-1 | Start Date*: 2021-11-15 | ||||||||||||||||||||||||||||||||||||
| Sponsor Name:Famewave Ltd. | ||||||||||||||||||||||||||||||||||||||
| Full Title: A Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CM24 in combination with nivolumab in adults with advanced solid tumours | ||||||||||||||||||||||||||||||||||||||
| Medical condition: Part A- Recurrent and metastatic non-small cell lung cancer (NSCLC), pancreatic cancer, ovarian cancer, papillary thyroid cancer, colorectal adenocarcinoma and melanoma Part B- Recurrent or metasta... | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
| Trial protocol: ES (Completed) | ||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2020-002468-30 | Sponsor Protocol Number: Met-DTC | Start Date*: 2021-02-16 | |||||||||||
| Sponsor Name:ENTE OSPEDALIERO OSPEDALI GALLIERA | |||||||||||||
| Full Title: Study of Metformin activity in patients with differentiated thyroid cancer metastasis with minimally progressive development | |||||||||||||
| Medical condition: patients with differentiated thyroid cancer metastasis with minimally progressive development | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2017-000800-59 | Sponsor Protocol Number: LOXO-RET-17001 | Start Date*: 2019-02-22 | |||||||||||||||||||||
| Sponsor Name:Loxo Oncology, Inc. a wholly owned subsidiary of Eli Lilly and Company | |||||||||||||||||||||||
| Full Title: A Phase 1/2 Study of Oral LOXO-292 in Patients with Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors with RET Activation (LIBRETTO-001) | |||||||||||||||||||||||
| Medical condition: Male or female patients age 12 years or older with a locally advanced or metastatic solid tumor with evidence of a RET gene alteration in tumor and/or blood | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) NL (Ongoing) DK (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
| EudraCT Number: 2006-000897-65 | Sponsor Protocol Number: MN2 | Start Date*: 2006-02-20 | |||||||||||
| Sponsor Name:AZIENDA OSPEDALIERA ARCISPEDALE S. MARIA NUOVA | |||||||||||||
| Full Title: Therapy of tumors SSTR2 expressing using somatostatine analogs labeled with 90Y and 177 Lu. | |||||||||||||
| Medical condition: Diagnosis of tumor classified as expressing SSRT2, the main class of tumors to be included in the study are advanced and metastatic neuroendocrine tumors but also breast, lungs and thyroid cancers... | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2013-001705-87 | Sponsor Protocol Number: BRF117019 | Start Date*: 2014-03-06 | |||||||||||
| Sponsor Name:GlaxoSmithKline Research & Development Ltd | |||||||||||||
| Full Title: A Phase II, Open-label, Study in Subjects with BRAF V600E Mutated Rare Cancers with Several Histologies to Investigate the Clinical Efficacy and Safety of the Combination Therapy of Dabrafenib and ... | |||||||||||||
| Medical condition: Mutations of BRAF V600E have been identified at a high frequency in melanoma, PTC, colorectal and ovarian cancers. Such mutations have also been reported in some rare cancers such as anaplastic t... | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Completed) SE (Completed) BE (Completed) AT (Completed) DK (Completed) NL (Completed) ES (Ongoing) NO (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2016-004618-93 | Sponsor Protocol Number: R120502 | Start Date*: 2017-12-12 | ||||||||||||||||
| Sponsor Name:University of Manchester | ||||||||||||||||||
| Full Title: Evaluation of the safety of CEdiranib in the prevention of Bowel perforation in platinum-resistant Ovarian Cancer | ||||||||||||||||||
| Medical condition: Platinum-Resistant Ovarian Cancer | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Female | |||||||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2008-003176-21 | Sponsor Protocol Number: TRIO 017 | Start Date*: 2008-12-31 | |||||||||||
| Sponsor Name:Cancer International Research Group | |||||||||||||
| Full Title: A phase II, open label multicenter trial of panobinostat (LBH589) monotherapy in women with HER2 negative locally recurrent or metastatic breast cancer | |||||||||||||
| Medical condition: Women with HER-2 negative locally recurrent or metastatic breast cancer; | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: FR (Completed) BE (Completed) IE (Completed) GB (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2015-005546-63 | Sponsor Protocol Number: DOTATER1_26_15 | Start Date*: 2016-05-30 | |||||||||||
| Sponsor Name:AZIENDA OSPEDALIERA ARCISPEDALE SANTA MARIA NUOVA/IRCCS DI REGGIO EMILIA | |||||||||||||
| Full Title: Peptide receptor radionuclide therapy in tumors with high expression of somatostatine receptors. | |||||||||||||
| Medical condition: Cancer patients with high expression of somatostatin receptors (neurendocrine tumors, thyroid tumors, lung tumors, meningiomas). | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2011-004426-10 | Sponsor Protocol Number: MO28072 | Start Date*: 2012-05-11 | |||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:F. Hoffman-La Roche Ltd. | |||||||||||||||||||||||||||||||||||||||||||
| Full Title: An open-label, phase II study of vemurafenib in patients with BRAF V600 mutation-positive cancers | |||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Patients with cancers (excluding melanoma and papillary thyroid cancer) harboring BRAF V600 mutations as identified by the routinely performed mutation analysis assays at each individual partici... | |||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: GB (Completed) ES (Completed) DE (Completed) | |||||||||||||||||||||||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2010-023827-34 | Sponsor Protocol Number: 1585/10 | Start Date*: 2011-05-02 | |||||||||||
| Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI | |||||||||||||
| Full Title: PHASE III CLINICAL TRIAL TO ASSESS THE ADDED ROLE OF 68Ga-DOTANOC PET-CT IN PATIENTS WITH NEUROENDOCRINE TUMORS | |||||||||||||
| Medical condition: neuroendocrine tumors | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2006-000320-14 | Sponsor Protocol Number: D6997L00002 (9238SW0001) | Start Date*: 2006-03-29 |
| Sponsor Name:AstraZeneca oy | ||
| Full Title: Anastrozole monotherapy versus maximal oestrogen blockage with anastrozole and fulvestrant comination therapy: An open, randomised, comparative, phase III multicentre study in postmenopausal women ... | ||
| Medical condition: Hormone receptor positive breast cancer in first relapse after primary treatment of localised tumour, in postmenopausal women. | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Female | |
| Trial protocol: FI (Completed) PT (Completed) IS (Completed) FR (Completed) IT (Completed) | ||
| Trial results: View results | ||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.
